Literature DB >> 24553362

The stubborn persistence of adult pneumococcal pneumonia as a public health problem.

Rosalind Hollingsworth1, Raul Isturiz1.   

Abstract

Entities:  

Keywords:  adults; bacterial; clinical; conjugate; pneumococcal; polysaccharide vaccine; protein conjugate vaccine; vaccination; vaccinology

Mesh：

Substances：

Year:  2014        PMID： 24553362      PMCID： PMC4896575          DOI： 10.4161/hv.27986

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  26 in total

1.  Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia.

Authors:  Thomas Bewick; Carmen Sheppard; Sonia Greenwood; Mary Slack; Caroline Trotter; Robert George; Wei Shen Lim
Journal:  Thorax       Date:  2012-02-28       Impact factor: 9.139

2.  Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years.

Authors:  Derek Weycker; Reiko Sato; David Strutton; John Edelsberg; Mark Atwood; Lisa A Jackson
Journal:  Vaccine       Date:  2012-06-20       Impact factor: 3.641

3.  Performance comparison of lung ultrasound and chest x-ray for the diagnosis of pneumonia in the ED.

Authors:  Jean-Eudes Bourcier; Julie Paquet; Mickael Seinger; Emeric Gallard; Jean-Philippe Redonnet; Fouad Cheddadi; Didier Garnier; Jean-Marie Bourgeois; Thomas Geeraerts
Journal:  Am J Emerg Med       Date:  2013-10-09       Impact factor: 2.469

4.  Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly.

Authors:  A Ortqvist; I Henckaerts; J Hedlund; J Poolman
Journal:  Vaccine       Date:  2006-09-20       Impact factor: 3.641

5.  Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.

Authors:  Kenneth J Smith; Angela R Wateska; Mary Patricia Nowalk; Mahlon Raymund; J Pekka Nuorti; Richard K Zimmerman
Journal:  JAMA       Date:  2012-02-22       Impact factor: 56.272

6.  Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults.

Authors:  Jennifer C Nelson; Michael Jackson; Onchee Yu; Cynthia G Whitney; Lora Bounds; Rachel Bittner; Ann Zavitkovsky; Lisa A Jackson
Journal:  Vaccine       Date:  2008-07-26       Impact factor: 3.641

7.  Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.

Authors:  Lisa A Jackson; Alejandra Gurtman; Martin van Cleeff; Kathrin U Jansen; Deepthi Jayawardene; Carmel Devlin; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma
Journal:  Vaccine       Date:  2013-05-18       Impact factor: 3.641

8.  High discordance of chest x-ray and computed tomography for detection of pulmonary opacities in ED patients: implications for diagnosing pneumonia.

Authors:  Wesley H Self; D Mark Courtney; Candace D McNaughton; Richard G Wunderink; Jeffrey A Kline
Journal:  Am J Emerg Med       Date:  2012-10-18       Impact factor: 2.469

9.  Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321

10.  Pneumococcal vaccination of older adults: conjugate or polysaccharide?

Authors:  Rosalind Hollingsworth; Raul Isturiz
Journal:  Hum Vaccin Immunother       Date:  2013-09-09       Impact factor: 3.452
View more
  3 in total

1.  What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?

Authors:  A T Newall
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452

2.  Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.

Authors:  David S Fedson
Journal:  Hum Vaccin Immunother       Date:  2014-04-14       Impact factor: 3.452

Review 3.  Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.

Authors:  Gerhard Falkenhorst; Cornelius Remschmidt; Thomas Harder; Eva Hummers-Pradier; Ole Wichmann; Christian Bogdan
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.